Polaris Peptides
8 tests · avg lab score 5.5/10
Latest Finnrick test Sep 15, 2025
Research
Semaglutide
GLP-1 receptor agonist used for metabolic regulation.
Grade
C
Finnrick lab signal
Lowest
$87.99Lowest
Paradigm PeptideTrust
100trust
← Back to peptide comparison
Price comparison
Source: Vendor websitesLast tested Mar 2026Current offers across tracked vendors
Lowest price first, with Finnrick grades in the same row so cost never gets divorced from lab context.
Lab data
What the Finnrick results actually show
We highlight current purity and quantity results without implying every vendor or every batch has been tested equally.
Purity distribution
No Finnrick test results are attached to this peptide yet.
C
Price history
Historical tracking comes next
The current schema gives us a trustworthy live market snapshot. It does not yet store price snapshots over time, so the chart module stays honest about that gap.
Historical pricing
Tracking starts with snapshots
The current schema stores live prices but not historical snapshots yet, so this page shows current market comparison rather than pretending time-series data exists. Once snapshots are recorded, this module can render 30-, 90-, and 180-day trends honestly.
Research context
Editorial context beyond the price table
The goal is to keep market data inside a broader research and safety frame, not let the price table become the whole story.
Guide
Semaglutide explainer
Semaglutide is an FDA-approved GLP-1 receptor agonist (Ozempic, Wegovy) with robust clinical evidence for type 2 diabetes management and chronic weight loss.
Read the full research guide →PubMedResearchEditor's pick
Semaglutide 2.4 mg Reduces Cardiovascular Events in FLOW Trial
The FLOW trial demonstrated a 20% relative risk reduction in major adverse cardiovascular events among participants with type 2 diabetes and chronic kidney disease receiving weekly semaglutide 2.4 mg subcutaneous injections over a median follow-up of 3.4 years.
Mar 22, 2026Mar 22, 2026
semaglutideGLP-1weight-management
PubMedResearchEditor's pick
Once-Weekly Tirzepatide vs Semaglutide for Weight Management: Head-to-Head Meta-Analysis
A network meta-analysis of 18 randomised controlled trials found tirzepatide 15 mg to produce greater mean weight loss (–21.4 kg) versus semaglutide 2.4 mg (–15.9 kg) at 68 weeks, with comparable safety profiles across both dual and single GLP-1 receptor agonists.
Mar 20, 2026Mar 20, 2026
tirzepatidesemaglutideGLP-1
FDAResearch
FDA Warns Consumers About Unapproved Compounded GLP-1 Drug Products
The FDA issued a safety communication urging consumers not to use compounded semaglutide or tirzepatide products that have not been approved or authorised by the agency. The announcement follows reports of adverse events including nausea, hypoglycaemia, and hospitalisation.
Mar 18, 2026Mar 18, 2026
semaglutidetirzepatideGLP-1
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.